Medtronic PLC (MDT)

Sep 28, 2026

MiniMed has appointed Sheila Denton as its new general counsel and corporate secretary. Denton brings over 25 years of experience in global pharmaceutical and biotech companies, with expertise in corporate governance, strategic transactions, intellectual property, and litigation. Her appointment is expected to help MiniMed scale as an independent public company, leveraging her experience in guiding companies through growth and transformation.

Sep 27, 2026

This article compares the turnaround strategies of Pfizer (NYSE: PFE) and Medtronic (NYSE: MDT), two healthcare giants. While Pfizer is focusing on newer medicines and cost reductions as its COVID revenue declines, Medtronic is seeing faster growth from its investments in cardiovascular, surgery, and neuroscience technologies. The article concludes that Medtronic's turnaround appears more convincing due to its stronger underlying revenue trajectory, although Pfizer's strategy could still yield substantial improvements if execution is successful.

Sep 27, 2026

The article compares Gilead Sciences (GILD) and Medtronic (MDT) as healthcare stock options, focusing on their growth prospects and income generation for investors. Gilead exhibits stronger pharmaceutical growth, particularly in its HIV portfolio, but has high concentration risk and significant R&D investments. Medtronic, on the other hand, shows more diversified growth across various medical technologies and boasts a 49-year record of dividend increases, despite recent growth figures being boosted by an extra fiscal week.

Sep 27, 2026

Medtronic (MDT) is focusing on accelerating growth through innovation platforms, strong core segments, and high-growth opportunities like robotic surgery and new devices. The company's recent collaboration with Cornerstone Robotics and a revised fiscal 2027 outlook signal a bullish future, with projected organic revenue growth of 7.25% to 7.75%. However, Medtronic faces intense competition from companies like Johnson & Johnson and Intuitive Surgical in these targeted growth markets, which could challenge its ability to capture significant market share.

Sep 25, 2026

This article provides a weekly rundown of significant medical marketing news, deal-making, FDA approvals, funding, and industry chatter involving major pharmaceutical companies. Key highlights include Eli Lilly's FDA approval for a once-weekly basal insulin, Bristol Myers Squibb and Johnson & Johnson announcing job cuts, and various strategic collaborations and financial activities across the healthcare sector.

Sep 24, 2026

Truist has initiated a Buy rating for MiniMed Group (MMED) with a $29 price target, citing a turnaround driven by increased investment, an improved business strategy, and new product launches. The analyst notes that MiniMed is benefiting from these factors following a period of under-investment by Medtronic (MDT).

Sep 24, 2026

Medtronic (MDT) has announced a $700 million strategic partnership with Cornerstone Robotics to distribute their Sentire surgical system in selected regions outside the U.S. This deal aims to broaden Medtronic's access to the robotic-assisted surgery market by offering tiered hardware options, complementing its proprietary Hugo system. While the investment increases Medtronic's debt exposure and introduces potential product overlap, it is seen as a strategic move to unlock immediate growth in underserved international markets by converting an expanded hardware footprint into recurring procedure revenue.

Sep 24, 2026

Precision Neuroscience, a brain-computer interface (BCI) technology company, has successfully closed an oversubscribed $250 million Series D financing round, bringing its total capital raised to $430 million. The funding, co-led by Pershing Square Inc., the Ackman Oxman Institute, and a prominent life sciences investment fund, will support the expansion of its clinical program, advance FDA review for its Layer 7™ cortical interface, and build commercialization infrastructure. This significant investment underscores growing confidence in BCI technology as a transformative force in healthcare and technology, recognizing Precision's leadership in the field through extensive clinical work and technological advancements.

Sep 24, 2026

Intuitive Surgical's stock has dropped 29% this year due to slowing procedure growth for its da Vinci robots, increased competition, and expiring ACA subsidies. Despite these headwinds, many analysts believe the sell-off is overdone, with a majority rating the stock as "buy" or "strong buy" and foreseeing significant upside due to long-term market potential and an aging demographic. Historically, similar declines have proven to be good buying opportunities for the medical device company.

Sep 24, 2026

Envestnet Asset Management Inc. reduced its stake in Medtronic PLC (NYSE:MDT) by 9.4% in the second quarter, selling 639,262 shares but still retaining 6.17 million shares valued at approximately $483 million. Despite this sale, institutional investors collectively own 82.06% of the company. Medtronic recently reported stronger-than-expected quarterly results, with adjusted EPS of $1.45 against a $1.39 consensus, and analysts maintain a "Moderate Buy" rating with an average price target of $103.92.

Sep 23, 2026

QRG Capital Management Inc. reduced its stake in Medtronic PLC (NYSE:MDT) by 6.6% in the second quarter, selling 21,296 shares. Despite this sale, Medtronic's stock is largely held by institutional investors, and the company recently reported strong quarterly earnings and raised its fiscal 2027 outlook. Analysts maintain a "Moderate Buy" rating with a consensus price target of $103.92, and Medtronic declared a quarterly dividend of $0.72.

Sep 23, 2026

The global minimally invasive robotic surgical system market is projected to reach $18.15 billion by 2030, growing from $8.9 billion in 2025 due to increased precision, patient outcomes, and adoption in outpatient facilities. Key growth drivers include improved reimbursement, precision medicine, and demand for minimally invasive procedures. Product innovation and strategic acquisitions by major players like Intuitive Surgical, Johnson & Johnson, and Medtronic are strengthening the market, with North America currently the largest regional market and Asia-Pacific expected to be the fastest-growing.

Sep 22, 2026

State Street Corp increased its stake in Medtronic PLC by 2.7%, purchasing an additional 1.66 million shares, bringing its total holdings to 63.4 million shares valued at approximately $5.0 billion. This comes as Medtronic reported stronger-than-expected quarterly results with an EPS of $1.45 and revenue of $9.76 billion, a 13.7% year-over-year increase. Despite an executive selling shares, analysts maintain a "Moderate Buy" consensus with a target price of $103.92, and the company also declared a quarterly dividend of $0.72 per share.

Sep 22, 2026

Penumbra, Inc. (PEN) is a medical devices company with a market cap of $12.51 billion, showing robust revenue growth and strong profitability. Analysts are cautiously optimistic, with an average target price suggesting a 13.93% upside potential. The company's strategic focus on innovation and expanding product offerings make it an intriguing opportunity for investors looking for capital appreciation in the healthcare sector.

Sep 17, 2026

Medtronic has raised its fiscal 2027 profit and revenue outlook for the second time, driven by strong demand for cardiovascular devices and double-digit growth across all major business segments. The company reported first-quarter revenue of $9.76 billion and adjusted earnings per share of $1.45, both exceeding analyst expectations. While new partnerships and product launches fuel optimism, Medtronic faces challenges including tariff headwinds and uncertainty surrounding the potential separation of its diabetes business.

Sep 17, 2026

Johnson & Johnson is exiting the left atrial appendage (LAA) closure market, selling the assets of its Laminar technology to Jaguar LAA, a newly formed private company. The move follows J&J's suspension of a pivotal trial for the Laminar device due to potential post-implant unwrapping and leaks. Jaguar, formed in partnership with Santé Ventures and Laminar's management, plans to continue developing the differentiated LAA closure technology.

Sep 17, 2026

The FDA has cleared Medtronic's LigaSure RAS Maryland jaw device for use with its Hugo robotic-assisted surgery (RAS) system in the US. This clearance introduces Medtronic's vessel-sealing technology for robotic-assisted procedures, particularly in urologic surgery, with plans to expand indications to other soft-tissue procedures. The device, already available in Europe, is designed for efficient vessel sealing and cutting with reduced thermal spread.

Sep 16, 2026

The US FDA has issued a warning to Bausch + Lomb, indicating a potential recall and production interruption for the company. This warning suggests that a recall would be necessary if the firm's response to the FDA's concerns is not deemed satisfactory. The article highlights the implications for Bausch + Lomb's ophthalmic supply chain and manufacturing operations.

Sep 16, 2026

Medtronic has received FDA clearance for its LigaSure RAS Maryland instrument, which will be integrated into its Hugo RAS robotic platform for robot-assisted surgery in the US. This clearance allows the company to incorporate its vessel-sealing technology, already widely used, into its leading robotic system, strengthening its offering in the growing robotic surgery market. The LigaSure RAS Maryland instrument, capable of sealing and cutting vessels up to 7mm, was previously introduced to the European market in 2025.

Sep 16, 2026

Edwards Lifesciences and Medtronic, leading medtech companies, have received positive news from CMS regarding expanded Medicare coverage for Transcatheter Aortic Valve Replacement (TAVR). CMS's finalized national coverage decision will now include patients with asymptomatic severe aortic stenosis and removes the evidence development requirement for symptomatic cases. This move is expected to streamline patient care, increase TAVR procedure volumes, and reinforces the value of multidisciplinary heart teams.

Sep 15, 2026

Medtronic has launched an exchange offer to spin off its diabetes business, MiniMed, making it an independent company. CEO Geoff Martha expressed confidence in MiniMed's strong results, innovation pipeline, and leadership, highlighting its robust position in the diabetes care market. This move allows Medtronic to focus its capital on cardiovascular, neuroscience, and surgical portfolios, while MiniMed gains flexibility as a full-stack diabetes tech player.

Sep 15, 2026

Analysts have given Medtronic PLC (NYSE:MDT) an average "Moderate Buy" recommendation, with 19 buy ratings and nine hold ratings among 28 firms. The average 12-month price target is $103.92, exceeding the current share price of $93.87. The company recently surpassed quarterly earnings expectations, reporting $1.45 in adjusted EPS and $9.76 billion in revenue, and announced a quarterly dividend of $0.72 per share, yielding 3.1%.

Sep 14, 2026

MiniMed announced it has filed a Form S-4 Registration Statement with the SEC regarding Medtronic's offer to exchange up to 225,361,295 shares of MiniMed common stock for Medtronic ordinary shares. This exchange offer signifies the final stage of MiniMed's separation from Medtronic, granting MiniMed complete autonomy over its capital allocation, product roadmap, and operational speed. Medtronic currently owns approximately 89.86% of MiniMed and will no longer hold an equity stake after the exchange offer is completed.